RNAi Therapeutic Platforms for Lung Diseases
RNA interference (RNAi) is rapidly becoming an important method for analyzing gene functions in many eukaryotes and holds promise for the development of therapeutic gene silencing. The induction of RNAi relies on small silencing RNAs, which affect specific messenger RNA (mRNA) degradation. Two types...
Saved in:
Main Authors: | Kazuyoshi Kuwano (Author), Takahiro Ochiya (Author), Fumitaka Takeshita (Author), Yu Fujita (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2013-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RNAi Therapeutics in Autoimmune Disease
by: Seunghee Cha, et al.
Published: (2013) -
The Business of RNAi Therapeutics in 2012
by: Dirk Haussecker
Published: (2012) -
Control of HCV Replication With iMIRs, a Novel Anti-RNAi Agent
by: Saori Itami, et al.
Published: (2015) -
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
by: John C. Burnett, et al.
Published: (2013) -
Using RNAi in the treatment of cardiovascular diseases - therapeutics based on siRNA overview
by: Barbara Rusinowska
Published: (2022)